UCLA researchers in the Department of Bioengineering at David Geffen School of Medicine developed a microfluidic device that can significantly promote cell reprogramming and direct induced neuronal reprogramming with high specificity. This invention is important for basic science, disease modeling, therapeutic testing, functionalizing knowledge for engineering improved replacement cells and tissues, and in situ regeneration and healing of cells already in or near the site of injury without the cancer risks of pluripotent cell products.
Contact UCLA Technology Development Group for more information.